Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medartis Holding AGXSWX:MED +2.45%85 Debt-to-EBITDA is 3.29 as of Dec. 2025, which is 50% above its 10-year median of 2.19. GuruFocus rates XSWX:MED with a GF Score™ of 85/100 and a GF Value™ of CHF107.25 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 470 Medical Devices & Instruments companies, Medartis Holding AG ranks worse than 72.77% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Medartis Holding AG's Debt-to-EBITDA or its related term are showing as below:
XSWX:MED'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.3 Med: 2.19 Max: 4.98
Current: 3.45
During the past 12 years, the highest Debt-to-EBITDA Ratio of Medartis Holding AG was 4.98. The lowest was 0.30. And the median was 2.19.
XSWX:MED's Debt-to-EBITDA is ranked worse than 72.77% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs XSWX:MED: 3.45
Medartis Holding AG (XSWX:MED) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Medartis Holding AG Debt-to-EBITDA Related Terms
Medartis Holding AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Medartis Holding AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MED vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Medartis Holding AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medartis Holding AG Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medartis Holding AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medartis Holding AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Medartis Holding AG (XSWX:MED) has a Debt-to-EBITDA of 3.29 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medartis Holding AG. This is 50% above median its historical median of 2.19. Over the past decade, Medartis Holding AG's Debt-to-EBITDA has ranged from 0.30 to 4.98. According to the industry distribution chart, Medartis Holding AG ranks #342 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 72.8%.
Is Medartis Holding AG's Debt-to-EBITDA too high?
Medartis Holding AG's current Debt-to-EBITDA of 3.29 is 50% above median its 10-year median of 2.19. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 4.98. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.59. Medartis Holding AG's value of 3.29 is 107.6% above this industry median. Based on the distribution chart, Medartis Holding AG ranks #342 out of 470 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medartis Holding AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medartis Holding AG's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medartis Holding AG ranks #342 out of 470 companies for Debt-to-EBITDA. This places Medartis Holding AG in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. Medartis Holding AG's value of 3.29 is 107.6% above this benchmark. Historically, Medartis Holding AG's own Debt-to-EBITDA has ranged from 0.30 to 4.98 over the past decade. While the company's 10-year median is 2.19 vs. the industry median of 1.59, Medartis Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medartis Holding AG's current Debt-to-EBITDA of 3.29 is 107.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medartis Holding AG. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medartis Holding AG's current Debt-to-EBITDA is 3.29, which is 50% above median its own 10-year median of 2.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medartis Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Medartis Holding AG (XSWX:MED) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF107.25, compared to a current price of CHF92.10 — trading 14.1% below its estimated fair value. The current Debt-to-EBITDA is 3.29, which is 50% above median its 10-year median of 2.19 and 107.6% above the Medical Devices & Instruments industry median of 1.59. Medartis Holding AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Medartis Holding AG (XSWX:MED), the current Debt-to-EBITDA is 3.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medartis Holding AG (XSWX:MED) Overvalued in 2026?
Based on GuruFocus' analysis, Medartis Holding AG stock appears to be undervalued.
The current stock price of CHF92.10 is trading 14.1% below its estimated GF Value™ of CHF107.25.
GuruFocus considers Medartis Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:MED:
Debt-to-EBITDA: 3.29 (50% above median its 10-year median of 2.19)
GF Value™: CHF107.25 vs. price of CHF92.10 (14.1% below fair value)
Industry Position: 107.6% above the Medical Devices & Instruments median (#342 of 470)
No single metric tells the full story. See the XSWX:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from Europe, Middle East and Africa (EMEA) and also has a presence in North America, Asia Pacific, and Latin America.
85GF Score
Get the complete analysis for XSWX:MED
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MED has been successfully added to your 
